Novel Antiplatelet Agents: The Current State and What Is Coming Down the Pike

Progress in Cardiovascular Diseases

Volumn 58, Issue 3, 2015, Pages 267-277

  Franchi, Francesco ^a   Rollini, Fabiana ^a   Park, Yongwhi ^a,b   Angiolillo, Dominick J ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b Gyeongsang National University   (South Korea)

Author keywords

Acute coronary syndrome; Antiplatelet therapy; P2Y12 receptor; Percutaneous coronary intervention; Thrombin receptor

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CANGRELOR; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; PLACEBO; PRASUGREL; RIVAROXABAN; TICAGRELOR; VORAPAXAR; NEW DRUG;

ACUTE CORONARY SYNDROME; ADJUVANT THERAPY; ANGIOCARDIOGRAPHY; ARTICLE; ATHEROSCLEROSIS; BLEEDING; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY DISEASE; DRUG OVERDOSE; DRUG WITHDRAWAL; DYSPNEA; HEART INFARCTION; HEMATOMA; HIGH RISK PATIENT; HOSPITAL READMISSION; HUMAN; LOADING DRUG DOSE; LOW DRUG DOSE; MAINTENANCE DRUG DOSE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; SECONDARY PREVENTION; STENT THROMBOSIS; TREATMENT DURATION; ADVERSE EFFECTS; BLOOD; CHEMICALLY INDUCED; COMPLICATION; CORONARY THROMBOSIS; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG EFFECTS; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; ORAL DRUG ADMINISTRATION; RISK ASSESSMENT; RISK FACTOR; SIGNAL TRANSDUCTION; THROMBOCYTE; THROMBOCYTE ACTIVATION; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; ADMINISTRATION, INTRAVENOUS; ADMINISTRATION, ORAL; BLOOD PLATELETS; CORONARY THROMBOSIS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; DRUGS, INVESTIGATIONAL; HEMORRHAGE; HUMANS; PERCUTANEOUS CORONARY INTERVENTION; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; RISK ASSESSMENT; RISK FACTORS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84952863872     PISSN: 00330620     EISSN: 18731740     Source Type: Journal    
DOI: 10.1016/j.pcad.2015.08.009     Document Type: Article

References (63)

1. Falk E., Nakano M., Bentzon J.F., et al. Update on acute coronary syndromes: the pathologists' view. Eur Heart J 2013, 34:719-728.
2. Franchi F., Angiolillo D.J. Novel antiplatelet agents in acute coronary syndrome. Nat Rev Cardiol 2015, 12:30-47.
3. Angiolillo D.J., Ueno M., Goto S. Basic principles of platelet biology and clinical implications. Circ J 2010, 74:597-607.
4. Amsterdam E.A., Wenger N.K., Brindis R.G., et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014, 130:e344-246.
5. Levine G.N., Bates E.R., Blankenship J.C., et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol 2011, 58:e44-e122.
6. Windecker S., Kolh P., Alfonso F., et al. 2014 ESC/EACTS guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2014, 35:2541-2619.
7. Mega J.L., Simon T. Pharmacology of antithrombotic drugs: an assessment of oral antiplatelet and anticoagulant treatments. Lancet 2015, 386:281-291. [Epub ahead of print].
8. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002, 324:71-86. Antithrombotic Trialists' Collaboration.
9. Mehta S.R., Bassand J.P., Chrolavicius S., et al. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med 2010, 363:930-942.
10. Angiolillo D.J. The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: from aspirin to the present day. Drugs 2012, 72:2087-2116.
11. Palmerini T., Benedetto U., Biondi-Zoccai G., et al. Long-term safety of drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. J Am Coll Cardiol 2015, 65:2496-2507.
12. Angiolillo D.J., Fernandez-Ortiz A., Bernardo E., et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol 2007, 49:1505-1516.
13. Tantry U.S., Bonello L., Aradi D., et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol 2013, 62:2261-2273.
14. Mega J.L., Braunwald E., Wiviott S.D., et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012, 366:9-19.
15. Angiolillo D.J., Ferreiro J.L. Antiplatelet and anticoagulant therapy for atherothrombotic disease: the role of current and emerging agents. Am J Cardiovasc Drugs 2013, 13:233-250.
16. Wiviott S.D., Braunwald E., McCabe C.H., et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007, 357:2001-2015.
17. Roe M.T., Armstrong P.W., Fox K.A., et al. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med 2012, 367:1297-1309.
18. Roe M.T., Goodman S.G., Ohman E.M., et al. Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel. Circulation 2013, 128:823-833.
19. Wiviott S.D., White H.D., Ohman E.M., et al. Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial. Lancet 2013, 382:605-613.
20. Montalescot G., Bolognese L., Dudek D., et al. Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. N Engl J Med 2013, 369:999-1010.
21. O'Gara P.T., Kushner F.G., Ascheim D.D., et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013, 61:e78-e140.
22. Wallentin L., Becker R.C., Budaj A., et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009, 361:1045-1057.
23. Bonaca M.P., Bhatt D.L., Cohen M., et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 2015, 372:1791-1800.
24. Cattaneo M., Schulz R., Nylander S. Adenosine-mediated effects of ticagrelor: evidence and potential clinical relevance. J Am Coll Cardiol 2014, 63:2503-2509.
25. Angiolillo D.J., Capodanno D., Goto S. Platelet thrombin receptor antagonism and atherothrombosis. Eur Heart J 2010, 31:17-28.
26. Franchi F., Rollini F., Park Y., Angiolillo D.J. Platelet thrombin receptor antagonism with vorapaxar: a review on pharmacology and clinical trial development. Future Cardiol 2015, [in press].
27. Tricoci P., Huang Z., Held C., et al. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med 2012, 366:20-33.
28. Morrow D.A., Braunwald E., Bonaca M.P., et al. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med 2012, 366:1404-1413.
29. Morrow D.A., Alberts M.J., Mohr J.P., et al. Efficacy and safety of vorapaxar in patients with prior ischemic stroke. Stroke 2013, 44:691-698.
30. Scirica B.M., Bonaca M.P., Braunwald E., et al. Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial. Lancet 2012, 380:1317-1324.
31. Magnani G., Bonaca M.P., Braunwald E., et al. Efficacy and safety of vorapaxar as approved for clinical use in the United States. J Am Heart Assoc 2015, 4:e001505.
32. Cavender M.A., Scirica B.M., Bonaca M.P., et al. Vorapaxar in patients with diabetes mellitus and previous myocardial infarction: findings from the thrombin receptor antagonist in secondary prevention of atherothrombotic ischemic events-TIMI 50 trial. Circulation 2015, 131:1047-1053.
33. Capodanno D., Angiolillo D.J. Management of antiplatelet and anticoagulant therapy in patients with atrial fibrillation in the setting of acute coronary syndromes or percutaneous coronary interventions. Circ Cardiovasc Interv 2014, 7:113-124.
34. Schulz S., Angiolillo D.J., Antoniucci D., et al. Randomized comparison of ticagrelor versus prasugrel in patients with acute coronary syndrome and planned invasive strategy-design and rationale of the iNtracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REACT) 5 trial. J Cardiovasc Transl Res 2014, 7:91-100.
35. Franchi F., Rollini F., Cho J.R., et al. Platelet function testing in contemporary clinical and interventional practice. Curr Treat Options Cardiovasc Med 2014, 16:300.
36. Alexopoulos D., Bhatt D.L., Hamm C.W., et al. Early P2Y12 inhibition in ST-segment elevation myocardial infarction: bridging the gap. Am Heart J 2015, 170:3-12.
37. Franchi F., Rollini F., Cho J.R., et al. Impact of escalating loading dose regimens of ticagrelor in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of a prospective randomized pharmacokinetic and pharmacodynamic investigation. JACC Cardiovasc Interv 2015, 8:1457-1469.
38. Parodi G., Xanthopoulou I., Bellandi B., et al. Ticagrelor crushed tablets administration in STEMI patients: the MOJITO study. J Am Coll Cardiol 2015, 65:511-512.
39. FDA Vorapaxar prescribing information [online] [Accessed on June 2015]. http://www.fda.gov/drugs/informationondrugs/ucm423935.htm.
40. Muñiz-Lozano A., Rollini F., Franchi F., Angiolillo D.J. Update on platelet glycoprotein IIb/IIIa inhibitors: recommendations for clinical practice. Ther Adv Cardiovasc Dis 2013, 7:197-213.
41. Stone G.W., Mehran R., Goldstein P., et al. Bivalirudin versus heparin with or without glycoprotein IIb/IIIa inhibitors in patients with STEMI undergoing primary percutaneous coronary intervention: pooled patient-level analysis from the HORIZONS-AMI and EUROMAX trials. J Am Coll Cardiol 2015, 65:27-38.
42. Franchi F., Rollini F., Muñiz-Lozano A., et al. Cangrelor: a review on pharmacology and clinical trial development. Expert Rev Cardiovasc Ther 2013, 11:1279-1291.
43. Harrington R.A., Stone G.W., McNulty S., et al. Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med 2009, 361:2318-2329.
44. Bhatt D.L., Lincoff A.M., Gibson C.M., et al. Intravenous platelet blockade with cangrelor during PCI. N Engl J Med 2009, 361:2330-2341.
45. Bhatt D.L., Stone G.W., Mahaffey K.W., et al. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med 2013, 368:1303-1313.
46. White H.D., Chew D.P., Dauerman H.L., et al. Reduced immediate ischemic events with cangrelor in PCI: a pooled analysis of the CHAMPION trials using the universal definition of myocardial infarction. Am Heart J 2012, 163:182-190.e4.
47. Steg P.G., Bhatt D.L., Hamm C.W., et al. Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data. Lancet 2013, 382:1981-1992.
48. Angiolillo D.J., Bhatt D.L., Steg P.G., et al. Impact of cangrelor overdosing on bleeding complications in patients undergoing percutaneous coronary intervention: insights from the CHAMPION trials. J Thromb Thrombolysis 2015, 40:17-22.
49. Cangrelor United Sates full prescribing information [online] [Accessed on June 2015]. http://www.kengreal.com/pdfs/kengreal-us-prescribing-information.pdf.
50. Cangrelor EMA prescribing information [online] [Accessed on June 2015]. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003773/WC500188098.pdf.
51. Rollini F., Franchi F., Angiolillo D.J. Switching P2Y12 receptor inhibitors in patients with coronary artery disease. Nat Rev Cardiol 2015, [Epub ahead of print]. 10.1038/nrcardio.2015.113.
52. Angiolillo D.J., Firstenberg M.S., Price M.J., et al. Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial. JAMA 2012, 307:265-274.
53. Capra V., Bäck M., Angiolillo D.J., et al. Impact of vascular thromboxane prostanoid receptor activation on hemostasis, thrombosis, oxidative stress, and inflammation. J Thromb Haemost 2014, 12:126-137.
54. Tello-Montoliu A., Jover E., Rivera J., et al. New perspectives in antiplatelet therapy. Curr Med Chem 2012, 19:406-427.
55. Schulz-Schüpke S., Byrne R.A., Ten Berg J.M., et al. ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12months of clopidogrel therapy after drug-eluting stenting. Eur Heart J 2015, 36:1252-1263.
56. Feres F., Costa R.A., Abizaid A., et al. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. JAMA 2013, 310:2510-2522.
57. Palmerini T., Benedetto U., Bacchi-Reggiani L., et al. Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomised trials. Lancet 2015, 385:2371-2382.
58. Giustino G., Baber U., Sartori S., et al. Duration of dual antiplatelet therapy after drug-eluting stent implantation: a systematic review and meta-analysis of randomized controlled trials. J Am Coll Cardiol 2015, 65:1298-1310.
59. Bhatt D.L., Flather M.D., Hacke W., et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol 2007, 49:1982-1988.
60. Mauri L., Kereiakes D.J., Yeh R.W., et al. Twelve or 30months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 2014, 371:2155-2166.
61. Yeh R.W., Kereiakes D.J., Steg P.G., et al. Benefits and risks of extended duration dual antiplatelet therapy after PCI in patients with and without acute myocardial infarction. J Am Coll Cardiol 2015, 65:2211-2221.
62. Price M.J. The optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: chasing a mirage. J Am Coll Cardiol 2015, 65:1311-1313.
63. Colombo A., Chieffo A. Dual antiplatelet therapy after drug-eluting stents-how long to treat?. N Engl J Med 2014, 371:2225-2226.